Filtros de búsqueda

Lista de obras de Caroline Robert

"Mycobacterium massilipolynesiensis" sp. nov., a rapidly-growing mycobacterium of medical interest related to Mycobacterium phlei

artículo científico publicado en 2017

'Cellulomonas timonensis' sp. nov., taxonogenomics description of a new bacterial species isolated from human gut.

artículo científico publicado en 2018

1215OResults of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma

1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

1245PQuality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma

1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

article

A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents

artículo científico publicado en 2016

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

artículo científico publicado en 2011

A decade of immune-checkpoint inhibitors in cancer therapy

artículo científico publicado en 2020

A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers

artículo científico publicado en 1999

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

artículo científico

Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation?

scientific article published on 17 July 2019

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

artículo científico publicado en 2018

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

artículo científico

Advances in the management of cutaneous toxicities of targeted therapies

artículo científico publicado en 2012

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients

artículo científico publicado en 2008

Analysis of dermatologic events in vemurafenib-treated patients with melanoma

artículo científico publicado en 2013

Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases

article

Anti-CTLA-4 antibody adjuvant therapy in melanoma

artículo científico publicado en 2010

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

artículo científico publicado en 2015

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

Arterial thrombosis and anti-PD-1 blockade

artículo científico publicado en 2017

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

artículo científico publicado en 2016

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

artículo científico publicado en 2015

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

artículo científico publicado en 2017

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

artículo científico publicado en 2019

Bullous amyloidosis. Report of 3 cases and review of the literature.

artículo científico publicado en 1993

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

artículo científico publicado en 2005

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

scientific article published on 18 January 2016

Carcinomes basocellulaires localement avancés traités par vismodégib : devenir des rémissions complètes après arrêt du traitement

artículo científico publicado en 2017

Cell survival and shuttle vector mutagenesis induced by ultraviolet A and ultraviolet B radiation in a human cell line

artículo científico publicado en 1996

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

artículo científico publicado en 2015

Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy

artículo científico publicado en 2017

Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases

artículo científico publicado en 2012

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.

artículo científico publicado en 2017

Combination of Triptorelin with Nivolumab in ICI Resistant Advanced Melanoma

artículo científico publicado en 2019

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

artículo científico publicado en 2014

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

artículo científico publicado en 2020

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

artículo científico publicado en 2016

Comparison of sun protection modalities in parents and children

scientific article published on 01 February 2015

Comparison of the gut microbiota of obese individuals from different geographic origins

Comparison of the gut microbiota of people in France and Saudi Arabia

artículo científico publicado en 2015

Complete genome sequence and description of Lactococcus garvieae M14 isolated from Algerian fermented milk

artículo científico publicado en 2016

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance

scientific journal article

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.

artículo científico publicado en 2016

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

artículo científico publicado en 2008

Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum-variant patients reveals 12 new disease-causing POLH mutations

artículo científico publicado en 2014

Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?

artículo científico publicado en 2008

Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample

artículo científico publicado en 2013

Cutaneous malignant melanoma in children and adolescents treated in pediatric oncology units

artículo científico publicado en 2016

Cutaneous side effects of sorafenib and sunitinib

artículo científico publicado en 2008

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors

artículo científico publicado en 2009

Cutaneous side-effects of kinase inhibitors and blocking antibodies

artículo científico publicado en 2005

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

artículo científico publicado en 2015

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

artículo científico publicado en 2012

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

artículo científico publicado en 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

artículo científico publicado en 2019

Dakarella massiliensis gen. nov., sp. nov., strain ND3T: a new bacterial genus isolated from the female genital tract

artículo científico publicado en 2017

Deleterious effects of ultraviolet A radiation in human cells

artículo científico publicado en 1997

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha

artículo científico publicado en 2009

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

artículo científico publicado en 2008

Description of erlotinib-related skin effects management in France. Results of the PRECEDE study

artículo científico publicado en 2009

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

artículo científico publicado en 2013

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial

artículo científico publicado en 2016

Draft genome sequence of Coxiella burnetii Dog Utad, a strain isolated from a dog-related outbreak of Q fever

artículo científico publicado en 2014

Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?

artículo científico publicado en 2014

Drancourtella massiliensis gen. nov., sp. nov. isolated from fresh healthy human faecal sample from South France

artículo científico publicado en 2016

Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies

artículo científico publicado en 2013

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

artículo científico publicado en 2017

EDIFICE Melanoma survey: knowledge and attitudes on melanoma prevention and diagnosis

artículo científico publicado en 2015

ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee

artículo científico publicado en 2020

ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee

artículo científico publicado en 2020

Effect of a fucose-rich polysaccharide preparation on the age-dependent evolution of the skin surface micro-relief ⬇️

artículo científico publicado el 1 de diciembre de 2003

Effect of a preparation containing a fucose-rich polysaccharide on periorbital wrinkles of human voluntaries

artículo científico publicado en 2005

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

scientific article published on 12 July 2016

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

artículo científico

Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas

artículo científico publicado en 2015

Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

artículo científico publicado en 2017

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

artículo científico publicado en 2018

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management

artículo científico publicado en 2017

Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis

artículo científico publicado en 1997

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Eruptive nevi associated with sorafenib treatment

artículo científico publicado en 2008

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

artículo científico publicado en 2016

Evolution of sun-protection measures for children.

artículo científico publicado en 2015

Expanded access programmes: patient interests versus clinical trial integrity

artículo científico publicado en 2014

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

artículo científico publicado en 2013

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

artículo científico publicado en 2011

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

artículo científico publicado en 2016

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

artículo científico publicado en 2017

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma

artículo científico publicado en 2013

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

artículo científico publicado en 2020

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

artículo científico publicado en 2019

Follicular lymphoma and Kaposi's disease arising successively in the same cutaneous area

artículo científico publicado en 1990

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

artículo científico publicado en 2014

Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL.

artículo científico publicado en 2009

Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study

artículo científico publicado en 2013

Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas

artículo científico publicado en 2008

Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma

artículo científico publicado en 2012

Genomic analysis of three African strains of Bacillus anthracis demonstrates that they are part of the clonal expansion of an exclusively pathogenic bacterium

artículo científico publicado en 2014

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib

artículo científico publicado en 2009

Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors

artículo científico publicado en 2014

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

artículo científico publicado en 2015

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

artículo científico publicado en 2016

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

artículo científico publicado en 2017

High-quality genome sequence and description of Paenibacillus dakarensis sp. nov.

artículo científico publicado en 2016

How cutaneous eruptions help to understand the mode of action of kinase inhibitors

scientific article published on 01 November 2012

Hypermetabolic dermatofibroma on Positron Emission Tomography/Computed tomography with 18F-FluoroDeoxyGlucose : a misleading false positive in the follow-up of a metastatic melanoma

artículo científico publicado en 2008

Hypodermal metastasis of malignant melanoma to the cheek

artículo científico publicado en 2013

Hypopigmented mycosis fungoides

artículo científico publicado en 1995

Hypopigmented mycosis fungoides in a light-skinned woman

artículo científico publicado en 1998

ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway

artículo científico publicado en 2008

Imaging of melanoma: usefulness of ultrasonography before and after contrast injection for diagnosis and early evaluation of treatment

artículo científico publicado en 2011

Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1.

artículo científico publicado en 2002

Immune Checkpoint Inhibitors

artículo científico

Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies

artículo científico

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

artículo científico publicado en 2016

Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm

artículo científico publicado en 2020

Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study

artículo científico publicado en 2016

Impact of dermatologic adverse events induced by targeted therapies on quality of life

artículo científico publicado en 2016

Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

artículo científico publicado en 2006

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

artículo científico publicado en 2010

Improved overall survival in melanoma with combined dabrafenib and trametinib

artículo científico publicado en 2015

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

artículo científico publicado en 2011

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

artículo científico publicado en 2017

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

artículo científico publicado en 2017

Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity

artículo científico publicado en 2000

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

artículo científico publicado en 2017

Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?

artículo científico publicado en 2012

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

artículo científico publicado en 2009

Kidney injuries related to ipilimumab

artículo científico

LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES

article

Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?

artículo científico publicado en 2005

Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors

artículo científico publicado en 2018

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

scientific article published on 18 September 2020

Longitudinal subungual acanthoma: one denomination for various clinical presentations

artículo científico publicado en 2018

Loss of Ambra1 promotes melanoma growth and invasion

artículo científico publicado en 2021

MAP-kinase pathway up or down? Just look at the skin of your patients!

artículo científico publicado en 2014

Malignant melanoma and granulomatosis

artículo científico publicado en 1997

Management and outcome of metastatic melanoma during pregnancy

artículo científico publicado en 2009

Management of Sentinel-Node Metastasis in Melanoma

artículo científico publicado en 2018

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

artículo científico publicado en 2015

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2017

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2018

Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse

scientific article published on January 2011

Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature

artículo científico publicado en 2012

Mechanisms of skin aging induced by EGFR inhibitors

artículo científico publicado en 2016

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma during fingolimod treatment for multiple sclerosis

scientific article published on 12 April 2019

Melanoma in 2011: a new paradigm tumor for drug development

artículo científico publicado en 2012

Melanoma risk-takers: fathers and sons

artículo científico publicado en 2015

Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion

artículo científico publicado en 2017

Metastatic melanoma: New paradigms of treatment and new toxicities

artículo científico publicado en 2013

Microbial culturomics: paradigm shift in the human gut microbiome study

artículo científico publicado en 2012

Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing

artículo científico publicado en 2009

Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment

artículo científico publicado en 2016

Multi-spacer typing as an effective method to distinguish the clonal lineage of Clostridium butyricum strains isolated from stool samples during a series of necrotizing enterocolitis cases

artículo científico publicado en 2016

Nail toxicities induced by systemic anticancer treatments

artículo científico

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

artículo científico publicado en 2009

Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma

scientific article published on 22 February 2019

New drugs in melanoma: it's a whole new world

artículo científico

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

artículo científico publicado en 2015

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

artículo científico publicado en 2017

Noncontiguous finished genome sequence and description of Gabonia massiliensis gen. nov., sp. nov.

artículo científico publicado en 2015

Noncontiguous finished genome sequence and description of Nocardioides massiliensis sp. nov. GD13(T)

artículo científico publicado en 2016

Noncontiguous finished genome sequence and description of Paenibacillus antibioticophila sp. nov. GD11(T), the type strain of Paenibacillus antibioticophila

artículo científico publicado en 2015

Noncontiguous finished genome sequence and description of Paenibacillus ihumii sp. nov. strain AT5.

artículo científico publicado en 2016

Noncontiguous finished genome sequence and description of Planococcus massiliensis sp. nov., a moderately halophilic bacterium isolated from the human gut

artículo científico publicado en 2016

Noncontiguous finished genome sequence and description of Virgibacillus massiliensis sp. nov., a moderately halophilic bacterium isolated from human gut.

artículo científico publicado en 2015

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

artículo científico publicado en 2004

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

article

P366 Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI)

artículo científico publicado en 2018

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition

artículo científico publicado en 2017

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma

artículo científico publicado en 2017

Pembrolizumab versus Ipilimumab in Advanced Melanoma

artículo científico publicado en 2015

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

artículo científico publicado en 2015

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

artículo científico publicado en 2017

Personal vs. intrinsic melanoma risk awareness: results of the EDIFICE Melanoma survey

artículo científico publicado en 2015

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

artículo científico publicado en 2010

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

artículo científico publicado en 2017

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

artículo científico publicado en 2013

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

artículo científico publicado en 2013

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

artículo científico publicado en 2007

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

artículo científico publicado en 2014

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

artículo científico publicado en 2015

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

scientific article published on 19 January 2010

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

artículo científico publicado en 2011

Pigmentary disorders induced by anticancer agents. Part II: targeted therapies

artículo científico publicado en 2013

Pigmentary disorders induced by anticancer agents. part I: chemotherapy

artículo científico publicado en 2013

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

artículo científico publicado en 2015

Pregnancy and melanoma: a European-wide survey to assess current management and a critical literature overview.

artículo científico publicado en 2016

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

artículo científico publicado en 2017

Prevalence of sunbed use, and characteristics and knowledge of sunbed users: results from the French population-based Edifice Melanoma survey

artículo científico publicado en 2015

Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria

artículo científico publicado en 2011

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

artículo científico publicado en 2016

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

artículo científico publicado en 2016

Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology.

artículo científico publicado en 2017

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

artículo científico publicado en 2013

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

artículo científico publicado en 2008

Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?

scientific article published on 03 February 2018

RAF inhibition and induction of cutaneous squamous cell carcinoma.

artículo científico publicado en 2011

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

artículo científico publicado en 2011

Radiotherapy as a risk factor for malignant melanoma after childhood skin hemangioma

artículo científico

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy

artículo científico publicado en 2016

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering

artículo científico publicado en 2013

Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergence

artículo científico publicado en 2013

Renal effects of immune checkpoint inhibitors

artículo científico publicado en 2016

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

artículo científico publicado en 2016

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

artículo científico publicado en 2009

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

artículo científico publicado en 2014

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

artículo científico publicado en 2016

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

artículo científico publicado en 2013

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

artículo científico publicado en 2018

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

artículo científico publicado en 2014

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

artículo científico publicado en 2016

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

artículo científico publicado en 2005

Salt in stools is associated with obesity, gut halophilic microbiota and Akkermansia muciniphila depletion in humans

article by E H Seck et al published 11 September 2018 in International Journal of Obesity

Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).

artículo científico publicado en 2009

Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization

artículo científico publicado en 2016

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

artículo científico publicado en 2013

Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma

artículo científico publicado en 2004

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

artículo científico publicado en 2013

Seminal vesicle metastasis of cutaneous malignant melanoma: An unusual and challenging presentation

artículo científico publicado en 2015

Sentinel lymph node biopsy in 33 non-melanoma skin cancers of the head and neck: A twelve-year experience with long-term follow-up

artículo científico publicado en 2018

Sentinel lymph node biopsy in cutaneous head and neck melanoma

scientific article published on 19 March 2018

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety

artículo científico publicado en 2011

Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?

Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab

artículo científico publicado en 2017

Side effects and toxicities of targeted therapies in stage IV melanoma

artículo científico

Small molecules and targeted therapies in distant metastatic disease.

scientific article published on August 2009

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

artículo científico publicado en 2011

Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.

artículo científico publicado en 2013

Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel.

artículo científico publicado en 2002

Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT)

artículo científico publicado en 2018

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

artículo científico publicado en 2005

Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.

artículo científico publicado en 2017

Sun exposure profile in the French population. Results of the EDIFICE Melanoma survey

artículo científico publicado en 2015

Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma

artículo científico publicado en 2009

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

artículo científico publicado en 2014

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

artículo científico

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

artículo científico publicado en 2017

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines

artículo científico publicado en 2016

Systemic Therapy Options for Patients With Unresectable Melanoma

artículo científico publicado en 2017

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

artículo científico publicado en 2020

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

artículo científico

Targeted therapy-induced radiation recall

artículo científico publicado en 2013

Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner

artículo científico publicado en 2017

The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy ⬇️

artículo científico

The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force

artículo científico publicado en 2020

The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics

artículo científico publicado en 2013

The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study.

artículo científico publicado en 2016

The plasticity of mRNA translation during cancer progression and therapy resistance

artículo científico publicado en 2021

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

artículo científico publicado en 2013

The proof of concept that culturomics can be superior to metagenomics to study atypical stool samples

article

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

artículo científico publicado en 2017

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib

artículo científico publicado en 2008

Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy.

artículo científico publicado en 2009

Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma.

artículo científico publicado en 2017

Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases

artículo científico publicado en 2018

Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.

artículo científico publicado en 2017

Treatment algorithms in stage IV melanoma

artículo científico

Treponema species enrich the gut microbiota of traditional rural populations but are absent from urban individuals

artículo científico publicado en 2018

Two cases of immune thrombocytopenia associated with pembrolizumab.

artículo científico publicado en 2015

Tyrosine kinase inhibition and grey hair

artículo científico publicado en 2003

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

artículo científico publicado en 2011

Update on the role of ipilimumab in melanoma and first data on new combination therapies

artículo científico publicado en 2013

Use of sorafenib in patients with hepatocellular or renal carcinoma

artículo científico publicado en 2010

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

artículo científico publicado en 2005

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors

artículo científico publicado en 2014

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

artículo científico publicado en 2017

Virgibacillus senegalensis sp. nov., a new moderately halophilic bacterium isolated from human gut

artículo científico publicado en 2015

Visceral lesions occurring during follow-up of melanoma patients: a true place for other diagnosis than melanoma metastasis

artículo científico publicado en 2011

What is new in oncodermatology?

artículo científico publicado en 2008

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

artículo científico publicado en 2009

Who benefits most from adjuvant interferon treatment for melanoma?

artículo científico publicado en 2015

[Axitinib in metastatic renal carcinomas: update of knowledge about side effects].

artículo científico publicado en 2014

[Knockout mice: advantages and limitations for biological modeling. Definitions, principles and examples]

artículo científico publicado en 1998

[Mechanisms of resistance to anti-BRAF treatments].

artículo científico publicado en 2014

[Misleading and rare form of vulvar carcinoma with fast development. Suspicion of human papillomavirus infection]

artículo científico publicado en 1990

[Necrotic ulcer patch mimicking factitious panniculitis disclosing systemic lupus erythematosus]

artículo científico publicado en 1990

[Physician-patient relations in dermatology]

artículo científico publicado en 1997

[Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma].

artículo científico publicado en 2014

[Rothmund-Thomson syndrome with reduced DNA repair capacity]

scientific article published on 01 January 1996

[Sezary syndrome with palmoplantar bullous lesions]

artículo científico publicado en 1992

[Systemic treatment of melanoma brain metastases].

artículo científico publicado en 2015

[Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].

artículo científico publicado en 2017

[Treating metastatic melanoma: Risk management].

artículo científico publicado en 2017

[Trichothiodystrophies: anomalies of the repair and transcription of genes]

scientific article published on 01 October 1999

[Xeroderma pigmentosum. What may be expected from biological studies?]

artículo científico publicado en 1994

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda